Association between incidence of acute exacerbation and medication therapy in patients with COPD

References

• GOLD Executive Committee. Global Strategy for the Diagnosis Management, and Prevention of Chronic Obstructive Pulmonary Disease: Global Initiative for Chronic Obstructive Lung Disease, 2006
   Google Scholar
• Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000;117:398-401S
   PubMed Web of Science ®Google Scholar
• Donaldson GC, Seemungal TA, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary diseases. Thorax 2002;57:847-52
   PubMed Web of Science ®Google Scholar
• Niewoehner DE. The impact of severe exacerbations on quality of life and the clinical course of chronic obstructive pulmonary disease. Am J Med 2006;119:38-45
   PubMed Web of Science ®Google Scholar
• Donaldson GC, Wedzicha JA. COPD exacerbations 1: epidemiology. Thorax 2006;61:164-8
   PubMed Web of Science ®Google Scholar
• O'Donnell DE, Parker CM. COPD exacerbations. 3: Pathophysiology. Thorax 2006;61:354-61
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Donaldson GC. Exacerbations of chronic obstructive pulmonary disease. Respir Care 2003;48:1204-15
   PubMedGoogle Scholar
• Seemungal TAR, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1418-22
   PubMed Web of Science ®Google Scholar
• Simoens S, Decramer M. Pharmacoeconomics of the management of acute exacerbations of chronic obstructive pulmonary disease. Expert Opin Pharmacother 2007;8:633-48
   PubMed Web of Science ®Google Scholar
• van Grunsven PM, van Schayck CP, Derenne JP, et al. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Thorax 1999;54:7-14
   PubMed Web of Science ®Google Scholar
• Sin DD, McAlister FA, Man SF, et al. Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA 2003;290:2301-12
   PubMed Web of Science ®Google Scholar
• Gartlehner G, Hansen RA, Carson SS, et al. Efficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-analysis of health outcomes. Ann Fam Med 2006;4:253-62
   PubMed Web of Science ®Google Scholar
• Salpeter SR, Buckley NS, Salpeter EE. Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD. J Gen Intern Med 2006;21:1011-19
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Nannini LJ, Rodríguez-Roisin R. Safety of long-acting beta-agonists in stable COPD: a systematic review. Chest 2008;133:1079-87
   PubMed Web of Science ®Google Scholar
• Calverly PMA, Anderson JA, Celli B. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89
   PubMed Web of Science ®Google Scholar
• Aaron SD, Fergusson D, Marks GB, et al. Counting, analysing and reporting exacerbations of COPD in randomised controlled trials. Thorax 2008;63:122-8
   PubMed Web of Science ®Google Scholar
• Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007;146:545-55
   PubMed Web of Science ®Google Scholar
• Akazawa M, Biddle AK, Stearns SC. Economic assessment of early initiation of inhaled corticosteroids in chronic obstructive pulmonary disease using propensity score matching. Clin Ther 2008;30:1003-16
   PubMed Web of Science ®Google Scholar
• Pauwels R, Calverley P, Buist AS, et al. COPD exacerbations: the importance of a standard definition. Respir Med 2004;98:99-107
   PubMed Web of Science ®Google Scholar
• DiPiro JT, Talbert RL, Yee CC, et al. Pharmacotherapy: A Pathophysiologic Approach, 6th edn. New York: McGraw-Hill, 2005
   Google Scholar
• Burge S, Wedzicha J. COPD exacerbations: definitions and classifications. Eur Respir J 2003;21:46-53s
   Web of Science ®Google Scholar
• Collett D. Modelling Survival Data in Medical Research. New York: Chapman & Hall, 1994
   Google Scholar
• Burnham KP, Anderson DR. Model Selection and Multimodel Inference: a Practical Information-Theoretic Approach, 2nd edn. New York: Springer-Verlag, 2002
   Google Scholar
• Akaike H. Information theory and an extension of the maximum likelihood principle. In: Petrov BN, Caski F, eds. Proceedings of the Second International Symposium on Information Theory. Budapest: Akademiai Kiado, 1973:267-81
   Google Scholar
• Klein JP, Moeschberger ML. Survival Analysis: Techniques for Censored and Truncated Data. New York: Springer-Verlag Inc., 1997
   Google Scholar
• Olsson U. Generalized Linear Models: An Applied Approach. Lund, Sweden: Studentlitteratur AB, 2003
   Google Scholar
• Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-55
   PubMed Web of Science ®Google Scholar
• Brusasco V, Hodder R, Miravitlles M, et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003;58:399-404
   PubMed Web of Science ®Google Scholar
• Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19:217-24
   PubMed Web of Science ®Google Scholar
• Vincken W, Noord JAv, Greefhorst APM, et al. Improved health outcomes in patients with COPD during 1 year’s treatment with tiotropium. Eur Respir J 2002;19:209-16
   PubMed Web of Science ®Google Scholar
• Aalbers R, Ayres J, Backer V, et al. Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial. Eur Respir J 2002;19:936-43
   PubMed Web of Science ®Google Scholar
• D'Urzo AD, Salvo MCd, Ramirez-Rivera A, et al. In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium: a 3-week, randomized, double-blind, within-patient, multicenter study. Chest 2001;119:1347-56
   PubMed Web of Science ®Google Scholar
• Dahl R, Greefhorst LAPM, Nowak D, et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:778-84
   PubMed Web of Science ®Google Scholar
• Rossi A, Kristufek P, Levine BE. Comparison of the efficacy, tolerability and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest 2002;121:1058-69
   PubMed Web of Science ®Google Scholar
• Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003;21:74-81
   PubMed Web of Science ®Google Scholar
• Calverley PM, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003;22:912-19
   PubMed Web of Science ®Google Scholar
• Decramer M, Celli B, Tashkin DP, et al. Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT trial. J COPD 2004;1:303-12
   PubMedGoogle Scholar
• Ferguson GT, Anzueto A, Fei R, et al. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. Respir Med 2008;102:1099-108
   PubMed Web of Science ®Google Scholar
• Lokke A, Lange P, Scharling H, et al. Developing COPD: a 25 year follow-up study of the general population. Thorax 2006;61:935-9
   PubMed Web of Science ®Google Scholar
• Sin DD. Is COPD really a cardiovascular disease?. Chest 2009;136:329-30
   PubMed Web of Science ®Google Scholar
• Niewoehner DE, Lohknygina Y, Rice K, et al. Risk indexes for exacerbations and hospitalizations due to COPD. Chest 2007;131:20-8
   PubMed Web of Science ®Google Scholar
• Stockley RA, Chopra N, Rice L. Addition of salmeterol to existing treatment in patients with COPD: a 12 month study. Thorax 2006;61:122-8
   PubMed Web of Science ®Google Scholar
• Rennard SI, Anderson W, ZuWallack R, et al. Use of long-acting inhaled beta2-adrenergic agonist salmeterol xinafoate in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:1087-92
   PubMed Web of Science ®Google Scholar
• Rossi A, Kristufek P, Levine BE, et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest 2002;121:1058-69
   PubMed Web of Science ®Google Scholar
• Hahn J. On the role of the propensity score in efficient semiparametric estimation of average treatment effects. Econometrica 1998;66:315-31
   Web of Science ®Google Scholar